| Patient | Elizabeth Barrett Browning |
|---|---|
| Date of birth | 1806-03-06 |
| Identifiers | MRN HR-NI026-SYN-TD; SSN (made up) 000-26-4157 |
| Document date | 1845-06-15 |
| Author | Clementine Haverford-Asante, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month review: final cultures, vitamin D, mood, safety, and the opioid dose. [S]
Ms. Barrett Browning returns three months after diagnosis. Her sputum is down to about a tablespoon a day and she has seen no blood since the first month. She had three nights of restlessness and lighter sleep after the first morphine step and then settled; she has taken no extra doses. She has had twelve grief therapy sessions and has begun to write about her brother, which she could not do before. She has gained almost 2 kg. She would like to take the next small step down. [S]
| Element | Detail |
|---|---|
| Lungs | About a tablespoon of sputum a day; no blood; no exacerbation |
| Opioid step | 9 mg twice daily for eight weeks; three restless nights, then settled |
| Grief therapy | Twelve sessions |
| Weight | 43.3 kg |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; energy better |
| Respiratory | Positive | Morning cough with a little sputum; no blood |
| Gastrointestinal | Negative | Stools regular; appetite better |
| Psychiatric | Negative | Mood lighter; no thoughts of self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Morphine sulfate 2 mg/mL oral solution, 5 mL (10 mg) by mouth twice daily, morning and bedtime (20 mg a day; long-standing prescription, continued) | 5 mL (10 mg) twice daily, morning and bedtime | Oral route | 1838-03-01 to 1845-04-19 | completed | S |
| Naloxone 4 mg nasal spray, one spray into one nostril for suspected opioid overdose, repeat in 2 to 3 minutes in the other nostril if no response; call 911 | As needed for suspected overdose; keep two devices at home | Nasal route | 1845-03-16 | active | S |
| Cholecalciferol (vitamin D3) 1000 unit (25 mcg) oral tablet, two tablets (1819 units) by mouth daily | Two tablets daily | Oral route | 1845-03-16 | active | S |
| Morphine sulfate 2 mg/mL oral solution, 4.5 mL (9 mg) by mouth twice daily, morning and bedtime (18 mg a day) | 4.5 mL (9 mg) twice daily, morning and bedtime | Oral route | 1845-04-20 to 1845-06-14 | completed | S |
| Morphine sulfate 2 mg/mL oral solution, 4 mL (8 mg) by mouth twice daily, morning and bedtime (16 mg a day) | 4 mL (8 mg) twice daily, morning and bedtime | Oral route | 1845-06-15 to 1845-10-18 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1845-06-15 | Body height | 157 | cm | S |
| 1845-06-15 | Body weight | 43.3 | kg | S |
| 1845-06-15 | Body mass index (BMI) [Ratio] | 17.6 | kg/m2 | S |
| 1845-06-15 | Systolic blood pressure | 106 | mm[Hg] | S |
| 1845-06-15 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 1845-06-15 | Heart rate | 84 | /min | S |
| 1845-06-15 | Respiratory rate | 16 | /min | S |
| 1845-06-15 | Body temperature | 36.7 | Cel | S |
| 1845-06-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1845-06-15 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 | ng/mL | 30 to 100 ng/mL sufficient; below 20 ng/mL deficient | Normal | S |
| 1845-06-15 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 1845-06-15 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 5 | {score} | S |
Vital signs recorded on 1845-06-15; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 43.3 kg |
| Respiratory | A few crackles at the left base only |
| Neurological | Not drowsy; no tremor, sweating or yawning |
| Psychiatric | Brighter; speaks of her brother with sadness but without being overwhelmed; no suicidal ideation |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic cough with daily yellow sputum, occasional streaks of blood, and breathlessness on stairs, worse in winter, for several years after an illness with blood in the sputum about eight years ago; tuberculosis, nontuberculous mycobacteria and bronchiectasis to be distinguished | resolved | confirmed | R05.3 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis at the consultation; it echoes her documented chest illness (D). |
| Non-cystic fibrosis bronchiectasis of the left lower lobe and lingula with chronic Haemophilus influenzae infection and mild airflow obstruction (Bronchiectasis Severity Index 3, mild); tuberculosis and nontuberculous mycobacterial disease excluded; synthetic modern diagnosis chosen for a historical chest illness whose cause is disputed | active | confirmed | J47.9 | S — Synthetic modern diagnosis; the nature of her historical chest illness remains undetermined (R, disputed). |
| Long-term prescribed opioid therapy (oral morphine 20 mg a day for many years, for cough, sleeplessness and palpitations), with expected physiological dependence; no opioid use disorder on DSM-5-TR assessment | active | confirmed | Z79.891 | S — Synthetic modern problem anchored to her documented prescribed opium (D); tolerance and withdrawal on prescribed opioids do not count toward opioid use disorder. |
| Prolonged grief disorder after the drowning of her closest brother five years ago, with yearning, self-blame, avoidance of reminders of the sea, and depressive symptoms (PHQ-9 12); no suicidal ideation | active | confirmed | F43.81 | S — Synthetic modern diagnosis anchored to her documented bereavement (D); not a claim about her real mental health. |
| Vitamin D deficiency (25-hydroxyvitamin D 15 ng/mL) in a woman who rarely goes outdoors | resolved | confirmed | E55.9 | S — Synthetic finding at intake; repleted by twelve weeks. |
| Underweight (BMI 16.8) with a small appetite | active | confirmed | R63.6 | S — Synthetic finding at intake. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Mycobacterial culture including nontuberculous mycobacteria | At diagnosis (final at six to eight weeks), then yearly and with unexplained decline | Completed today | Final at eight weeks: no growth of Mycobacterium tuberculosis or nontuberculous mycobacteria; next yearly |
| Laboratory | Sputum bacterial culture | At each review and at every exacerbation, before antibiotics | Completed today | Normal flora only |
| Self-management | Airway clearance technique and exercise | Every visit | Completed today | Twice daily; sputum about a tablespoon a day |
| Self-management | Exacerbations: number in the past year, written plan, and rescue antibiotic | Every visit | Completed today | None since diagnosis |
| Self-management | Hemoptysis: amount, and when to seek emergency care | Every visit | Completed today | None since the first month |
| Imaging | Spirometry and Bronchiectasis Severity Index | At diagnosis, then yearly | Up to date | Next at one year |
| Medication safety | Opioid benefits and harms: function, sleep, cough, sedation, breathing, constipation, and her goals | Every visit, and at least every three months | Completed today | No sedation; sleep and function better; second step chosen |
| Medication safety | Dose reduction at her request: withdrawal symptoms and sleep | Four weeks after each step | Completed today | Three restless nights after the first step, then settled; no extra doses |
| Medication safety | Prescription drug monitoring program check | With every prescription, and at least every three months | Completed today | One prescriber, one pharmacy |
| Medication safety | Urine drug test | At the start of review, then at least yearly | Up to date | Consistent with morphine only at intake; next at one year |
| Medication safety | Naloxone at home, and no benzodiazepines or other sedatives | Every visit | Completed today | Naloxone in date at home; no sedatives |
| Survey | PHQ-9 | At least monthly during active treatment (CMID) | Completed today | 7, from 10; GAD-7 5 |
| Examination | Suicide risk review and safety plan | Every visit | Completed today | No suicidal ideation; plan current |
| Self-management | Grief therapy attendance and response | Weekly for sixteen sessions | Completed today | Twelve sessions attended |
| Laboratory | 25-hydroxyvitamin D | Twelve weeks after starting replacement, then yearly; target 30 ng/mL or more (CMID) | Completed today | 34 ng/mL; next yearly |
| Examination | Weight and BMI | Every visit | Completed today | 43.3 kg, BMI 17.6 |
Goal progress:
Guideline basis: British Thoracic Society Guideline for Bronchiectasis in Adults (2019); Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017); Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline (2020); CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (2022); Shear MK, et al. Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial (2016); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression and osteoporosis monographs (2026)
Follow-up: Preventive visit next month. Seven-month review in the autumn with the PHQ-9, sputum culture, the influenza vaccine and the next opioid decision. Emergency care for more than a few teaspoons of blood. Next scheduled visit 1845-07-13: periodic adult preventive visit. [S]